[go: up one dir, main page]

PL2444120T3 - Spirocyklicze analogi amiloridu jako blokery ENac - Google Patents

Spirocyklicze analogi amiloridu jako blokery ENac

Info

Publication number
PL2444120T3
PL2444120T3 PL11184004T PL11184004T PL2444120T3 PL 2444120 T3 PL2444120 T3 PL 2444120T3 PL 11184004 T PL11184004 T PL 11184004T PL 11184004 T PL11184004 T PL 11184004T PL 2444120 T3 PL2444120 T3 PL 2444120T3
Authority
PL
Poland
Prior art keywords
spirocyclic
enac blockers
amiloride analogues
amiloride
analogues
Prior art date
Application number
PL11184004T
Other languages
English (en)
Inventor
Gurdip Bhalay
Emma Budd
Graham Charles Bloomfield
Stephen Paul Collingwood
Andrew Dunstan
Lee Edwards
Peter Gedeck
Catherine Howsham
Peter Hunt
Thomas Anthony Hunt
Paul Oakley
Nichola Smith
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2444120T3 publication Critical patent/PL2444120T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Processing Or Creating Images (AREA)
  • Image Analysis (AREA)
  • Image Processing (AREA)
PL11184004T 2007-12-10 2008-12-09 Spirocyklicze analogi amiloridu jako blokery ENac PL2444120T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07122739 2007-12-10
EP11184004.7A EP2444120B1 (en) 2007-12-10 2008-12-09 Spirocyclic amiloride analogues as ENac blockers
EP08860731.2A EP2231280B1 (en) 2007-12-10 2008-12-09 Amiloride-like Pyrazine-carboxamides as ENaC blockers

Publications (1)

Publication Number Publication Date
PL2444120T3 true PL2444120T3 (pl) 2018-02-28

Family

ID=39322745

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11184004T PL2444120T3 (pl) 2007-12-10 2008-12-09 Spirocyklicze analogi amiloridu jako blokery ENac

Country Status (30)

Country Link
US (5) US8039472B2 (pl)
EP (3) EP2520574A1 (pl)
JP (1) JP5455922B2 (pl)
KR (1) KR101578235B1 (pl)
CN (1) CN101939054B (pl)
AR (1) AR069637A1 (pl)
AU (1) AU2008334629B2 (pl)
BR (1) BRPI0820669A2 (pl)
CA (1) CA2707857C (pl)
CL (1) CL2008003651A1 (pl)
CO (1) CO6310968A2 (pl)
CR (1) CR11470A (pl)
CU (1) CU23967B1 (pl)
EA (1) EA017919B1 (pl)
EC (1) ECSP10010242A (pl)
ES (2) ES2602331T3 (pl)
HN (1) HN2010001165A (pl)
IL (1) IL206165A0 (pl)
MA (1) MA31894B1 (pl)
MX (1) MX2010006421A (pl)
MY (1) MY152955A (pl)
NZ (1) NZ585789A (pl)
PE (1) PE20091096A1 (pl)
PL (1) PL2444120T3 (pl)
PT (1) PT2444120T (pl)
TN (1) TN2010000256A1 (pl)
TW (1) TWI439462B (pl)
UA (1) UA104997C2 (pl)
WO (1) WO2009074575A2 (pl)
ZA (1) ZA201003837B (pl)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL2444120T3 (pl) * 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
BRPI0907823A2 (pt) 2008-02-26 2015-07-21 Parion Sciences Inc Bloqueadores poliaromáticos dos canais de sódio
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
US8664237B2 (en) * 2008-10-02 2014-03-04 The Johns Hopkins University Spiperone derivatives and methods of treating disorders
AR074060A1 (es) 2008-10-23 2010-12-22 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
JP5671453B2 (ja) * 2009-04-28 2015-02-18 中外製薬株式会社 スピロイミダゾロン誘導体
WO2010138794A2 (en) 2009-05-29 2010-12-02 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
EP2490687A1 (en) * 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8389727B2 (en) 2009-10-23 2013-03-05 Vertex Pharmaceuticals Incorporated Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide
JP5789611B2 (ja) 2009-10-23 2015-10-07 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス
US8404849B2 (en) 2010-05-20 2013-03-26 Vertex Pharmaceuticals Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
PT2760821T (pt) 2011-09-02 2018-01-11 Novartis Ag Sal de colina de um composto anti-inflamatório de ciclobutenodiona substituída
CN104024231A (zh) * 2011-11-02 2014-09-03 勃林格殷格翰国际有限公司 制备酰基胍和酰基硫脲化合物的新方法
PT2773633T (pt) 2011-11-02 2017-11-14 Boehringer Ingelheim Int Compostos heterocíclicos, medicamentos contendo os referidos compostos, sua utilização e processos para a sua preparação
US8809340B2 (en) * 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
WO2013158121A1 (en) 2012-04-20 2013-10-24 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8841309B2 (en) * 2012-09-24 2014-09-23 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
PL2914248T5 (pl) 2012-11-02 2024-01-15 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR
RS57190B1 (sr) 2012-12-10 2018-07-31 Chugai Pharmaceutical Co Ltd Derivat hidantoina
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CN104995178B (zh) 2012-12-17 2018-06-26 帕里昂科学公司 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
WO2014107622A1 (en) 2013-01-07 2014-07-10 University Of Southern California Deoxyuridine triphosphatase inhibitors
DE202013000888U1 (de) 2013-01-29 2014-05-05 WKW Erbslöh Automotive GmbH Vorrichtung zur Abdeckung eines in Längsrichtung eines Kraftfahrzeuges verlaufenden Dachkanals
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
JP6353032B2 (ja) * 2013-04-30 2018-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
JP2016525508A (ja) * 2013-07-02 2016-08-25 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 嚢胞性線維症の処置のための化合物
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9790214B2 (en) 2014-01-03 2017-10-17 University Of Southern California Heteroatom containing deoxyuridine triphosphatase inhibitors
UY36034A (es) 2014-03-18 2015-09-30 Astrazeneca Ab Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos
EP2932966A1 (en) 2014-04-16 2015-10-21 Novartis AG Gamma secretase inhibitors for treating respiratory diseases
WO2015189901A1 (ja) 2014-06-09 2015-12-17 中外製薬株式会社 ヒダントイン誘導体含有医薬組成物
JP2017536334A (ja) 2014-10-08 2017-12-07 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ナトリウムチャネルの改善されたペプチド阻害剤
BR112017009194A2 (pt) 2014-10-31 2017-12-26 Abbvie Sarl tetra-hidropiranos substituídos e método de uso
EP3245201B1 (en) * 2015-01-12 2019-06-19 Boehringer Ingelheim International GmbH Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
US20180002312A1 (en) * 2015-01-12 2018-01-04 Boehringer Ingelheim International Gmbh Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
EP3245199B1 (en) * 2015-01-12 2020-01-01 Boehringer Ingelheim International GmbH Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
WO2016193812A1 (en) 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use
FR3038605B1 (fr) * 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
AU2016290987C1 (en) 2015-07-08 2023-07-20 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
WO2017006283A1 (en) 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
TWI720032B (zh) 2015-10-09 2021-03-01 比利時商葛萊伯格有限公司 Ｎ－磺醯化吡唑并﹝３，４－ｂ﹞吡啶－６－甲醯胺及其使用方法
MX2018004364A (es) 2015-10-09 2018-08-16 Abbvie Sarl Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
AU2016333907A1 (en) 2015-10-09 2018-04-12 AbbVie S.à.r.l. Novel compounds for treatment of cystic fibrosis
US10402062B2 (en) * 2016-04-16 2019-09-03 Apple Inc. Organized timeline
CA3016303A1 (en) 2016-04-26 2017-11-02 Abbvie S.A.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098208A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US20200123137A1 (en) 2016-12-20 2020-04-23 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
JP2022518778A (ja) * 2019-01-28 2022-03-16 フラットリー ディスカバリー ラブ，エルエルシー 嚢胞性線維症の治療のための化合物および方法
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
CN114981243A (zh) 2019-11-12 2022-08-30 健赞公司 用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
US20220211692A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2023034992A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
CN113880735A (zh) * 2021-11-08 2022-01-04 湖北九宁化学科技有限公司 一种双氟磺酰二乙胺锂的制备方法
EP4583972A1 (en) 2022-09-07 2025-07-16 Sionna Therapeutics Inc. Macrocyclic compounds, compositions, and methods of using thereof
WO2024054845A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
WO2024054851A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions and methods of using thereof
WO2025132358A1 (en) 2023-12-21 2025-06-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL27897A (en) * 1966-08-25 1972-02-29 Merck & Co Inc Preparation of pyrazinoalguanides and pyrazinoamidoguanidines
NL6707564A (pl) * 1966-08-25 1968-02-26
US3328404A (en) * 1966-08-25 1967-06-27 Merck & Co Inc Derivatives of pyrazine
US3432502A (en) * 1966-08-25 1969-03-11 Merck & Co Inc Preparation of pyrazinoylguanidine and pyrazinamidoguanidine products
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US3503972A (en) * 1968-11-04 1970-03-31 Merck & Co Inc Alkyl n-amidino (or guanidino)-pyrazinimidates
US3577418A (en) * 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) * 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4246406A (en) 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4277602A (en) * 1980-07-02 1981-07-07 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4272537A (en) * 1980-07-02 1981-06-09 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(4,4-disubstituted-6-substituted-1,3,5-triazin-2-yl)-2-pyrazinecarboxamides
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
EP0300431A3 (en) 1987-07-22 1990-06-27 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
MX9301943A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2000000531A1 (en) 1998-06-30 2000-01-06 The Dow Chemical Company Polymer polyols and a process for the production thereof
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
EP1175402B1 (en) 1999-05-04 2005-07-20 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
ES2244437T3 (es) 1999-05-04 2005-12-16 Schering Corporation Derivados de piperazina utiles como antagonistas de ccr5.
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
TR200909479T2 (tr) 1999-08-21 2012-02-21 Nycomed Gmbh Sinerjistik kombinasyon.
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
EP1305300A1 (de) 2000-04-27 2003-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel
US6916828B2 (en) 2000-06-27 2005-07-12 Laboratorios S.A.L.V.A.T., S.A. Carbamates derivatived from arylakylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
DE10056400A1 (de) 2000-11-14 2002-05-23 Merck Patent Gmbh Galenische Formulierung
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
PT1353919E (pt) 2000-12-28 2006-11-30 Almirall Prodesfarma Ag Novos derivados de quinuclidina e composições medicinais contendo os mesmos
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2288543T3 (es) 2001-03-08 2008-01-16 Glaxo Group Limited Agonistas de beta-adrenorreceptores.
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
ES2307751T3 (es) 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
CA2677781C (en) 2001-06-21 2013-01-29 Verenium Corporation Nitrilases
CA2458534C (en) 2001-09-14 2011-11-01 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
PL370087A1 (pl) 2001-10-17 2005-05-16 Ucb, S.A. Pochodne chinuklidyny, sposoby ich wytwarzania i ich zastosowanie jako inhibitorów receptorów muskarynowych m2 i/lub m3
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
US7268152B2 (en) 2002-03-26 2007-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082280A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
AU2003239880A1 (en) 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
ES2282667T3 (es) 2002-06-25 2007-10-16 Merck Frosst Canada Ltd. Inhibidores de pde4 8-(biaril)quinolinas.
JP2005538972A (ja) 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンｐｄｅ４阻害剤
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
CA2494650A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
WO2004017974A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
HRP20050197A2 (en) 2002-08-10 2006-06-30 Altana Pharma Ag Piperidine-n-oxide-derivatives
RS20050117A (sr) 2002-08-17 2007-06-04 Altana Pharma Ag., Novi benzonaftiridini
JP2005537312A (ja) 2002-08-17 2005-12-08 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のフェナントリジン
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
ATE403648T1 (de) 2002-08-21 2008-08-15 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
DE60231341D1 (de) 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
ES2349164T3 (es) 2002-08-29 2010-12-28 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de 3-(sulfonamidoetil)-indol para uso como compuestos miméticos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alérgicas y proliferativas.
CA2496459C (en) 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
ES2279215T3 (es) 2002-08-29 2007-08-16 Altana Pharma Ag 2-hidroxi-6-fenilfenantridinas como inhibidores de pde-4.
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
CN1688577A (zh) 2002-09-18 2005-10-26 小野药品工业株式会社 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
WO2004026248A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
BR0315234A (pt) 2002-10-11 2005-08-23 Pfizer Derivados de indol como agonistas beta-2
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
EP1554264B1 (en) 2002-10-22 2007-08-08 Glaxo Group Limited Medicinal arylethanolamine compounds
AU2003269317B2 (en) 2002-10-23 2009-10-29 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
DK1556342T3 (da) 2002-10-28 2008-07-21 Glaxo Group Ltd Phenethanolaminderivat til behandling af respiratoriske sygdomme
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
AU2004207482B2 (en) 2003-01-21 2009-10-08 Merck Sharp & Dohme Corp. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1601657A1 (en) 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazole modulators of atp-binding cassette transporters
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
WO2004108765A2 (en) 2003-06-10 2004-12-16 Ace Biosciences A/S Extracellular aspergillus polypeptides
CN1898221A (zh) 2003-09-06 2007-01-17 沃泰克斯药物股份有限公司 Atp－结合弹夹转运蛋白的调控剂
US7700637B2 (en) 2003-09-17 2010-04-20 Novartis Ag Organic compounds
CA2540978A1 (en) 2003-10-08 2005-04-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
WO2005075435A1 (en) 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7939558B2 (en) 2004-06-04 2011-05-10 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
EP1865949B1 (en) 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RU2007138584A (ru) 2005-03-18 2009-04-27 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение
CA2609392A1 (en) 2005-05-24 2006-11-30 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
ATE512145T1 (de) 2005-08-11 2011-06-15 Vertex Pharma Modulatoren des cystic fibrosis transmembrane conductance regulators
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
GB0526240D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP1976528A2 (en) 2005-12-29 2008-10-08 Janssen Pharmaceutica, N.V. Prokineticin 2 receptor antagonists
US7893257B2 (en) 2006-12-14 2011-02-22 Janssen Pharmaceutica Nv Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
ES2436658T3 (es) 2007-12-10 2014-01-03 Synthon B.V. Síntesis de paliperidona
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Also Published As

Publication number Publication date
CU23967B1 (es) 2013-12-27
EP2520574A1 (en) 2012-11-07
US9139586B2 (en) 2015-09-22
EP2231280B1 (en) 2016-08-10
TN2010000256A1 (en) 2011-11-11
CU20100118A7 (es) 2011-10-14
WO2009074575A3 (en) 2009-08-13
CN101939054A (zh) 2011-01-05
ES2602331T3 (es) 2017-02-20
TW200930717A (en) 2009-07-16
US8039472B2 (en) 2011-10-18
JP2011506386A (ja) 2011-03-03
TWI439462B (zh) 2014-06-01
IL206165A0 (en) 2010-12-30
US8697687B2 (en) 2014-04-15
KR101578235B1 (ko) 2015-12-16
MA31894B1 (fr) 2010-12-01
CL2008003651A1 (es) 2009-06-19
EA201000886A1 (ru) 2011-02-28
WO2009074575A2 (en) 2009-06-18
EA017919B1 (ru) 2013-04-30
ES2654395T3 (es) 2018-02-13
US20100130506A1 (en) 2010-05-27
NZ585789A (en) 2012-03-30
CA2707857A1 (en) 2009-06-18
US20140171421A1 (en) 2014-06-19
AU2008334629A1 (en) 2009-06-18
CO6310968A2 (es) 2011-08-22
AU2008334629B2 (en) 2012-04-12
BRPI0820669A2 (pt) 2020-08-04
MX2010006421A (es) 2010-06-25
CA2707857C (en) 2016-09-13
ECSP10010242A (es) 2010-08-31
EP2231280A2 (en) 2010-09-29
US20130012500A1 (en) 2013-01-10
AR069637A1 (es) 2010-02-10
PE20091096A1 (es) 2009-08-25
CR11470A (es) 2010-07-09
HN2010001165A (es) 2012-11-12
EP2444120A1 (en) 2012-04-25
ZA201003837B (en) 2011-03-30
MY152955A (en) 2014-12-15
UA104997C2 (uk) 2014-04-10
KR20100098682A (ko) 2010-09-08
CN101939054B (zh) 2014-10-29
PT2444120T (pt) 2018-01-03
US9643983B2 (en) 2017-05-09
JP5455922B2 (ja) 2014-03-26
US20160068546A1 (en) 2016-03-10
US20110237572A1 (en) 2011-09-29
EP2444120B1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
PL2444120T3 (pl) Spirocyklicze analogi amiloridu jako blokery ENac
ZA201104592B (en) Glucagon analogues
ZA201104593B (en) Glucagon analogues
IL213477A0 (en) Glucagon analogues
ZA201104591B (en) Glucagon analogues
TWI367581B (en) Circuit structure
GB0805963D0 (en) Aircraft structure
IL225155A (en) History of pirazine as enac blockers
PL2519250T3 (pl) Analogi interferonu
IL210391A0 (en) Buprenorphine analogs
SI2225271T1 (sl) Novi selektivni analogi somatostatina
ZA201006733B (en) Oxytocin analogues
EP2515654A4 (en) NEW ERGOLINANALOGA
EP2285379A4 (en) ANALOGUES OF 1-METHYLNICOTINAMIDE
EP2197879A4 (en) CAMPTOTHECIN ANALOGUES SUBSTITUTED IN C7
TWM373005U (en) Gallium-nitride LED structure
EP2197279A4 (en) C10-SUBSTITUTED CAMPTOTHECIN ANALOG
GB0815020D0 (en) Aircraft structure
GB2487804B (en) Tri-color LED module structure
TWM371833U (en) LED module structure
TWM374156U (en) Improved LED structure
TWM374155U (en) Light-emitting module
TWM402988U (en) LED module combination structure
TWM389738U (en) Decoration board module
PL385219A1 (pl) Paralotnia